Genetics Testing in Parkinson's Disease

Genetic testing in Parkinson's disease can play an important role in diagnosing the illness. Scientists hope that the knowledge provided by genetics will ultimately help slow or stop its progression.

Genes are carried in our DNA, units of inheritance that determine the traits that are passed down from parent to child. We inherit about 3 billion pairs of genes from our mothers and fathers. They determine the color of our eyes, how tall we may be and, in some instances, the risk we have in developing certain diseases.

As a physician, I know the role that genetics plays in determining our health. The degree of influence that our genes have varies depending on the disease, but both environmental factors and genetics contribute to the development of illness to some extent.

Woman doing genetic testing

Andrew Brookes / Getty Images 

Genetics Testing in Parkinson's Disease

In Parkinson’s disease, the vast majority of cases are what we call sporadic with no identifiable cause. These "non-familial" cases mean no other family members have Parkinson’s. However, approximately 14 percent of people affected with Parkinson's have a first-degree relative (parent, sibling or child) that is also living with the disease. In these familial cases, the mutated genes that are causing this disease can be inherited in either a dominant pattern or recessive one.

Many affected relatives throughout different generations are usually found in families that have a dominant Parkinson’s gene. An example of this type of inheritance is the genetic mutation SNCA which results in the production of a protein called alpha-synuclein. This protein makes up Lewy bodies that are found in the brains of individuals with Parkinson’s. Other mutations – LRRK2, VPS35, and EIF4G1 – are also inherited dominantly.

In contrast, recessive mutations that act as a risk factor for the development of Parkinson’s disease are represented by cases within one generation as in siblings. The genetic mutations PARKIN, PINK1, and DJ1 genes are examples of this type of inheritance.

These are some of the mutations that are known but there are more that are being discovered on an ongoing basis. Keep in mind, however, that most genetic forms have low rates of expression or penetrance which basically means that just because you have the gene does not mean you will get Parkinson’s. Even in the case of LRRK2 mutations, which are dominant in nature, the presence of the gene does not equal the development of the disease.

When Should Genetic Testing Be Done?

Your physician may suggest it if your Parkinson’s diagnosis comes at a young age (less than 40 years old), if multiple relatives in your family history have also been diagnosed with the same, or if you are at high risk for familial Parkinson’s based on your ethnicity (those with Ashkenazi Jewish or North-African backgrounds).

However, what is the benefit of having the testing done at the present time? The information may be important for family planning for some individuals although as I said even if the gene is passed on it does not necessarily equal development of the disease. The risk, though, is higher in dominant genetic mutations versus recessive ones, on average if a person has a first-degree relative with Parkinson’s (ie. a parent or a sibling) their risk of developing the disease is 4 to 9 percent more than the general population.

Keep in mind that currently for the person being tested, there is no change in the treatment of their Parkinson’s disease based on genetic findings. In the future, however, when there are treatments to slow down the onset of the disease or to prevent it from developing at all, then the identification of those people at risk will be very important.

Genetics Testing and Research

Although there may be no direct benefit to you at the present time, the results of genetic testing can help further Parkinson’s research by allowing scientists to better understand the disease and consequently develop new treatments. For example, a mutation in the gene that codes for the protein alpha-synuclein (SNCA) leads to a specific type of familial Parkinson’s disease. Although this mutation only accounts for a small percentage of cases, knowledge of this mutation has had broader effects. The study of this genetic mutation led to the discovery that alpha-synuclein clumps together to form Lewy bodies which have been consistently found in the brains of all individuals with Parkinson’s disease not just those with the SNCA mutation. Thus, one gene mutation has led to a critical finding in the field of Parkinson’s research.

Genetics testing is a very personal decision but a cautionary note: anytime that genetic testing is considered, particularly in a disease condition where there is no change in treatment based on genetic findings, it would be my recommendation to see a genetics counselor to discuss the impact this information will have on you the patient and your family.

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  • Beck, James, Ph.D. "Parkinson's Insights: Genetic Testing and You.Parkinson's Insights: Genetic Testing and You. Parkinson's Disease Foundation (PDF), 26 Mar. 2013. 
  • Farrer, Matthew, MD. "Genetics: A Foundation for Future Parkinson's Treatments." - Parkinson's Disease Foundation (PDF). Parkinson's Disease Foundation, Winter 2012. 
  • Puschmann, Andreas. "Genetics of Parkinson's." Genetics of Parkinson's. European Parkinson's Disease Association, n.d. 

By Soania Mathur, MD
 Soania Mathur, MD, is a speaker, author, and advocate for people living with Parkinson's disease.